Evidence map›Paper›PMID 41878958›Full record

ArticleJournal of chromatography. B, Analytical technologies in the biomedical and life sciences2025

Determination of the pyrrolo[2,3-d] pyrimidine antifolate AGF94 from a preclinical murine study using a simple UHPLC-MS/MS assay.

Tryston T Metz, Rachel C Ashe, Alexis C Duncan, Ethan C Wilner, Keith T Schmidt, Kristbjorn O Gudmundsson, Zhanjun Hou, Aleem Gangjee, Larry H Matherly, Serguei V Kozlov and 1 more

Abstract read
In one paragraph

Article in Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Tryston T MetzClinical Pharmacology Program, National Cancer Institute, Bethesda, MD, United States of America.
Rachel C AsheClinical Pharmacology Program, National Cancer Institute, Bethesda, MD, United States of America.
Alexis C DuncanClinical Pharmacology Program, National Cancer Institute, Bethesda, MD, United States of America.
Ethan C WilnerClinical Pharmacology Program, National Cancer Institute, Bethesda, MD, United States of America.
Keith T SchmidtClinical Pharmacology Program, National Cancer Institute, Bethesda, MD, United States of America.
Kristbjorn O GudmundssonCenter for Advanced Preclinical Research, Frederick National Laboratory for Cancer Research, Frederick, MD, United States of America.
Zhanjun HouBarbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, MI, United States of America.
Aleem GangjeeSchool of Pharmacy, Duquesne University, Pittsburgh, PA, United States of America.
Larry H MatherlyBarbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, MI, United States of America.
Serguei V KozlovCenter for Advanced Preclinical Research, Frederick National Laboratory for Cancer Research, Frederick, MD, United States of America.
William D FiggClinical Pharmacology Program, National Cancer Institute, Bethesda, MD, United States of America. Electronic address: figgw@mail.nih.gov.

Funding

Using Clinical Pharmacology Principles to Develop New Anticancer TherapiesZICSC006537 · NCI · DIVISION OF CLINICAL SCIENCES - NCI · PI FIGG, WILLIAM DOUGLAS · 2009 to 2025
$14.4M
Therapeutic Targeting Mitochondrial C1 MetabolismR01CA250469 · NCI · WAYNE STATE UNIVERSITY · PI DANN, CHARLES E., GANGJEE, ALEEM · 2021 to 2025
$3.0M
Sample Processing and Analytical Methods Development for New Anticancer AgentsZ01SC006536 · SC · DIVISION OF CLINICAL SCIENCES - NCI · PI FIGG, WILLIAM DOUGLAS · 1997 to 2008
$731k
Intramural NIH HHS Z01 SC006536Intramural NIH HHS Z99 CA999999Intramural NIH HHS ZIC SC006537NCI NIH HHS R01 CA250469
6 · The paper itself

Abstract

A UHPLC-MS/MS method for the detection and quantification of the 6-substituted pyrrolo[2,3-d] pyrimidine AGF94, a novel antifolate, in mouse plasma and tissue was developed and validated. The developed method relies on a simple protein precipitation with methanol, followed by separation on a C18 column using a gradient solvent system of acetonitrile and water with 0.1 % formic acid in both. Detection and quantification of AGF94 were achieved by multiple reaction monitoring using a Sciex QTRAP 5500 mass spectrometer operated in positive electrospray ionization mode. The transitions for AGF94 and the internal standard were m/z 448 to 137 and 442 to 295, respectively. The calibration curve ranged from 5 to 500 ng/mL in mouse plasma with a linearity of R

Indexed as

Folic Acid AntagonistsPyrimidinesPyrrolesTandem Mass SpectrometryAnimalsChromatography, High Pressure LiquidDrug StabilityLimit of DetectionLinear ModelsMaleMiceReproducibility of ResultsFolic Acid AntagonistsPyrimidinesPyrrolesAntifolatesBioanalytical methodMass spectrometryPreclinical studyUHPLC

Identifiers

PMID41878958
PMCPMC13015840

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.